Unaudited Financial results for the quarter ended June 30, 2026

Q1FY27 results (unaudited): Consolidated: Revenue 80.7bn -6% y-y (85.5bn) EBITDA 10.1bn -62% y-y (26.8bn) EBITDA margin 12.5% (26.7%) -1420 bps y-y PAT 4.4bn -69% y-y (14.2bn) FY26 results (audited): Consolidated: Revenue 337.0bn +1% y-y (335.9bn) EBITDA omitted due to incomplete components PAT 42.9bn +3% y-y (41.6bn) Q1FY27 results (unaudited): Standalone: Revenue 51.4bn -34% y-y (78.1bn) EBITDA omitted due to incomplete components PAT 4.0bn -86% y-y (29.6bn) FY26 results (audited): Standalone: Revenue 205.3bn -2% y-y (209.0bn) EBITDA omitted due to incomplete components PAT 32.2bn -14% y-y (37.5bn) Dividend: Not stated Commentary: Q1FY27 performance reflected expected transition beyond lenalidomide revenues and an unexpected impact related to semaglutide API; underlying base business delivered healthy double-digit growth across key geographies.